SCHEMBL6921074

SCHEMBL6921074

CCn1nc(-c2ccccc2)c(C(=O)c2cccnc2)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.48
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PDE4B Q07343 1/20 0.43
PLOD2 O00469 1/20 0.43
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
APP P05067 1/20 0.41
GAA P10253 1/20 0.41
HCAR3 P49019 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
MAPT P10636 1/20 0.41
GRM1 Q13255 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ADORA2A P29274 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6920919 0.94 TBXAS1 (0.52) TBXAS1HPGDALOX15HSD17B10HTT
SCHEMBL6919975 0.86 F2 (0.44) TBXAS1HPGDALOX15HSD17B10PLOD2
SCHEMBL6916106 0.84 LMNA (0.46) HPGDPLOD2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL6921278 0.82 TSHR (0.46) HPGDALOX15HSD17B10PLOD2HTT
SCHEMBL6919541 0.81 HTT (0.41) HPGDALOX15HSD17B10HTTALDH1A1
SCHEMBL6922174 0.81 MAPT (0.43) HPGDALOX15HSD17B10PLOD2HTT
SCHEMBL6918790 0.81 LMNA (0.42) HPGDALOX15HSD17B10PLOD2HTT
SCHEMBL6922335 0.79 MAPT (0.41) HPGDALOX15HSD17B10HTTSMN1; SMN2
SCHEMBL6919643 0.78 L3MBTL1 (0.46) TBXAS1HPGDALOX15HSD17B10HTT
SCHEMBL6920008 0.77 L3MBTL1 (0.41) HPGDALOX15HSD17B10HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004033431-A2 HYDROXYPYRAZOLES FOR USE AGAINST METABOLIC-RELATED DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2004-04-22 WO claimed
WO-2004033431-A2 HYDROXYPYRAZOLES FOR USE AGAINST METABOLIC-RELATED DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2004-04-22 WO disclosed